149 related articles for article (PubMed ID: 19688982)
1. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma.
Maleddu A; Pantaleo MA; Castellucci P; Astorino M; Nanni C; Nannini M; Busato F; Di Battista M; Farsad M; Lodi F; Boschi S; Fanti S; Biasco G
Tumori; 2009; 95(3):382-4. PubMed ID: 19688982
[TBL] [Abstract][Full Text] [Related]
2. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
[TBL] [Abstract][Full Text] [Related]
3. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
Horn KP; Yap JT; Agarwal N; Morton KA; Kadrmas DJ; Beardmore B; Butterfield RI; Boucher K; Hoffman JM
Cancer Imaging; 2015 Sep; 15(1):15. PubMed ID: 26335224
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy for Renal Cell Carcinoma.
Joshi R; Rawal S
JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
[TBL] [Abstract][Full Text] [Related]
5. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive factor?
Gambini D; Locatelli E; Gianelli U; Bareggi C; Galassi B; Visintin R; Massironi S; Dell'orto PG; Tomirotti M
Anticancer Res; 2014 Dec; 34(12):7361-5. PubMed ID: 25503173
[TBL] [Abstract][Full Text] [Related]
7. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
Kayani I; Avril N; Bomanji J; Chowdhury S; Rockall A; Sahdev A; Nathan P; Wilson P; Shamash J; Sharpe K; Lim L; Dickson J; Ell P; Reynolds A; Powles T
Clin Cancer Res; 2011 Sep; 17(18):6021-8. PubMed ID: 21742806
[TBL] [Abstract][Full Text] [Related]
8. Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report.
Messina C; Di Meglio A; Nuzzo PV; Boccardo F; Ricci F
Tumori; 2015; 101(3):e79-81. PubMed ID: 26417621
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.
Vercellino L; Bousquet G; Baillet G; Barré E; Mathieu O; Just PA; Desgrandchamps F; Misset JL; Hindié E; Moretti JL
Cancer Biother Radiopharm; 2009 Feb; 24(1):137-44. PubMed ID: 19243256
[TBL] [Abstract][Full Text] [Related]
10. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.
Kalra S; Rini BI; Jonasch E
Ann Oncol; 2015 Jul; 26(7):1300-4. PubMed ID: 25628443
[TBL] [Abstract][Full Text] [Related]
11. Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma.
Ballardini P; Margutti G; Aliberti C; Manfredini R
Clin Drug Investig; 2009; 29(7):487-490. PubMed ID: 19499966
[TBL] [Abstract][Full Text] [Related]
12. Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.
Seidel C; Fenner M; Merseburger AS; Reuter C; Ivanyi P; Länger F; Ganser A; Grünwald V
World J Urol; 2011 Jun; 29(3):355-60. PubMed ID: 21258806
[TBL] [Abstract][Full Text] [Related]
13. Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma.
You D; Song SH; Cho YM; Lee JL; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
World J Urol; 2015 Jan; 33(1):111-8. PubMed ID: 24710685
[TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma.
García-Campelo R; Quindós M; Vázquez DD; López MR; Carral A; Calvo OF; Soto JM; Grande E; Durana J; Antón-Aparicio LM
Anticancer Drugs; 2010 Jan; 21 Suppl 1():S13-5. PubMed ID: 20110781
[TBL] [Abstract][Full Text] [Related]
15. Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature.
Karaca H; Lale A; Dikilitas M; Ozkan M; Er O
Med Oncol; 2010 Sep; 27(3):1023-6. PubMed ID: 19830602
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Méjean A; Ravaud A; Thezenas S; Colas S; Beauval JB; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Beisland C; Aitchison M; Oudard S; Patard JJ; Theodore C; Chevreau C; Laguerre B; Hubert J; Gross-Goupil M; Bernhard JC; Albiges L; Timsit MO; Lebret T; Escudier B
N Engl J Med; 2018 Aug; 379(5):417-427. PubMed ID: 29860937
[TBL] [Abstract][Full Text] [Related]
17. When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.
Sbitti Y; Debbagh A; Slimani K; Mahi M; Errihani H; Ichou M
J Med Case Rep; 2018 Mar; 12(1):80. PubMed ID: 29554941
[TBL] [Abstract][Full Text] [Related]
18. A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.
Powles T; Kayani I; Sharpe K; Lim L; Peters J; Stewart GD; Berney D; Sahdev A; Chowdhury S; Boleti E; Shamash J; Reynolds AR; Jones R; Blank C; Haanen J; Bex A
Ann Oncol; 2013 Aug; 24(8):2098-103. PubMed ID: 23579815
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group.
Lainakis G; Bamias A; Psimenou E; Fountzilas G; Dimopoulos MA
Clin Nephrol; 2009 Jul; 72(1):73-8. PubMed ID: 19640391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]